Allakos Inc. (NASDAQ:ALLK) Short Interest Update

Allakos Inc. (NASDAQ:ALLK) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 1,940,000 shares, a decline of 18.8% from the February 13th total of 2,390,000 shares. Based on an average daily volume of 2,190,000 shares, the short-interest ratio is currently 0.9 days. Approximately 2.6% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ALLK. Piper Sandler downgraded shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Citizens Jmp cut shares of Allakos from a “strong-buy” rating to a “hold” rating in a report on Monday, January 27th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $2.00.

Allakos Trading Up 0.9 %

Allakos stock opened at $0.26 on Thursday. The stock has a market cap of $23.23 million, a PE ratio of -0.13 and a beta of 0.72. The stock has a 50-day moving average price of $0.44 and a 200 day moving average price of $0.77. Allakos has a 52 week low of $0.23 and a 52 week high of $1.56.

Institutional Trading of Allakos

A number of hedge funds have recently bought and sold shares of ALLK. ADAR1 Capital Management LLC acquired a new position in shares of Allakos during the 4th quarter valued at about $75,000. Jane Street Group LLC raised its holdings in Allakos by 92.6% in the fourth quarter. Jane Street Group LLC now owns 101,097 shares of the company’s stock valued at $122,000 after buying an additional 48,602 shares during the period. Bridgeway Capital Management LLC grew its stake in Allakos by 25.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 209,900 shares of the company’s stock worth $254,000 after buying an additional 42,500 shares during the period. RBF Capital LLC boosted its position in Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after purchasing an additional 160,529 shares during the period. Finally, Tang Capital Management LLC raised its position in Allakos by 736.4% in the fourth quarter. Tang Capital Management LLC now owns 378,552 shares of the company’s stock valued at $458,000 after purchasing an additional 333,290 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.